Home Tags Generics

Tag: Generics

Evaluating the Size of Reverse Payments In Light of the Supreme...

James Langenfeld, Dec 30, 2013 Patent settlement agreements that involve payments from brand-name drug manufacturers to generic drug manufacturers (so called "reverse payments" or "pay...

Where Is the Italian Supreme Administrative Court Going in the Never-Ending...

Daniela Ampollini, Jul 15, 2013 It is obvious to all that know even a little of patent law, that the validity (and, even before, the...

Abuse of Regulatory Procedures in the Pharmaceutical Sector Developments Since the...

Patrick Harrison, Kristina Nordlander, Jul 27, 2012 In June 2005, the European Commission issued a decision finding that AstraZeneca had breached Article 102 TFEUby engaging...

From Astra-Zeneca to Pfizer: When Protection of Originators Patents Ceases to...

Stefano Grassani, Jul 27, 2012 On Jan. 11, 2012, the Italian Antitrust Authority ("IAA") found Pfizer Inc. and its Swedish and Italian subsidiaries guilty of...

Looking for Sense in the Italian Antitrust Authority Decision in the...

Daniela Ampollini, Jul 27, 2012 The January 2012 decision of the Italian Antitrust Authority ("IAA") in the Pfizer case, involving Pfizer's actions to counter the marketing...

European Commission Enforcement in the Pharmaceutical Sector: Less Than Expected? The...

Sean-Paul Brankin, Jul 27, 2012 On July 6, 2011, the European Commission closed the case file in itsBoehringer/Almirall investigation. It did so without a formal...

Pharmaceutical Patents, Settlements, Reverse Payments, and Exclusion: Update

John Bigelow, Jul 27, 2012 In the June issue of this Chronicle my fellow contributors and I described a trend in appellate court decisions involving...

Pharmaceutical Patents, Settlements, Reverse Payments, and Exclusion

John Bigelow, Jun 27, 2012 Cases involving pharmaceuticals settlements to patent litigation with so called "reverse payments" or, as the FTC now prefers to call...

Cervantes Sequel: The FTC’s Quest to End Pay-for-Delay Pharma Settlements

Anne Layne-Farrar, Jun 27, 2012 We are drawing close to the thirtieth anniversary of the Drug Price Competition and Patent Term Restoration Act, better known...

Reverse Payment Settlements: Presumptively Bad or Usually Acceptable?

Kyle Musgrove, Richard Ripley, Jun 27, 2012 In April 2012, the Federal Trade Commission ("FTC") suffered yet another rebuke of what FTC Chair Jon Leibowitz...

News

Antitrust Mix by CPI